Key result
Current use of rofecoxib (OR 1.32; 95% CI 1.09-1.61), diclofenac (OR 1.55), and ibuprofen (OR 1.24) was associated with a significantly increased risk of myocardial infarction compared with no use.
Why the study?
Does current use of cyclo-oxygenase-2 inhibitors or conventional NSAIDs increase the risk of myocardial infarction in primary care patients?
Population
95,567 patients from 367 UK general practices, comprising 9,218 cases with a first ever diagnosis of…
Comparison
Current use of cyclo-oxygenase-2 inhibitors or… vs No use of these drugs within the previous three…
Design
Case-control
Follow-up
4 years
Authors
Loading...
May warrant caution with NSAIDs in primary care; extends observational signals but leaves causality open.
Case-Control (n=95,567)
Yes
Does current use of cyclo-oxygenase-2 inhibitors or conventional NSAIDs increase the risk of myocardial infarction in primary care patients?
Odds Ratio: 1.32 (95% CI 1.09–1.61)
Current use of several NSAIDs, including rofecoxib, diclofenac, and ibuprofen, is associated with a significantly increased risk of myocardial infarction in a primary care population.
Hippisley–Cox et al. (2005) conducted a case-control in Myocardial infarction (n=95,567). Rofecoxib vs. No use within the previous three years was evaluated on Myocardial infarction (adjusted OR 1.32, 95% CI 1.09 to 1.61). Current use of rofecoxib (OR 1.32; 95% CI 1.09-1.61), diclofenac (OR 1.55), and ibuprofen (OR 1.24) was associated with a significantly increased risk of myocardial infarction compared with no use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: